Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells

被引：9

作者：

Tang, Xiaolong ^{[1
]}

Xie, Chunmei ^{[2
]}

Jiang, Zhenyou ^{[3
,4
]}

Li, Amin ^{[1
]}

Cai, Shiyu ^{[1
]}

Hou, Changhao ^{[1
]}

Wang, Jian ^{[1
]}

Liang, Yong ^{[5
,6
]}

Ma, Dong ^{[7
]}

机构：

[1] Anhui Univ Sci & Technol, Med Coll, Huainan, Peoples R China

[2] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Lab Med, Guangzhou, Guangdong, Peoples R China

[3] Jinan Univ, Dept Microbiol, Guangzhou, Guangdong, Peoples R China

[4] Jinan Univ, Dept Immunol, Guangzhou, Guangdong, Peoples R China

[5] Xuzhou Med Coll, Huaian Hosp, Huaian, Peoples R China

[6] Huaian Second Hosp, Huaian, Peoples R China

[7] Jinan Univ, Dept Biomed Engn, Guangdong Higher Educ Inst, Key Lab Biomat, Guangzhou, Guangdong, Peoples R China

来源：

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY | 2018年 / 46卷

基金：

中国国家自然科学基金;

关键词：

Non-Hodgkin's lymphoma; mTOR; signal pathways; rituximab; nanoparticles; TOR serine-threonine kinases; AZD-2014; NON-HODGKINS-LYMPHOMA; PRECLINICAL EVALUATION; INHIBITOR; MTOR; METABOLISM; ACTIVATION; INITIATION; APOPTOSIS; PATHWAYS; GROWTH;

D O I：

10.1080/21691401.2018.1478844

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.

引用

页码：1063 / 1073

页数：11

共 34 条

[1] Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies [J].

Awan, Farrukh T. ;

Gore, Lia ;

Gao, Lei ;

Sharma, Jyoti ;

Lager, Joanne ;

Costa, Luciano J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (01) :55-65

[2] Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells [J].

Chen, Li-Min ;

Song, Tian-Jiao ;

Xiao, Jian-Hong ;

Huang, Zheng-Hui ;

Li, Yong ;

Lin, Ting-Yan .

ONCOTARGET, 2017, 8 (38) :63911-63922

[3] Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives [J].

Chiappella, Annalisa ;

Castellino, Alessia ;

Nicolosi, Maura ;

Santambrogio, Elisa ;

Vitolo, Umberto .

EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (04) :289-297

[4] Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models [J].

Crafter, Claire ;

Vincent, John P. ;

Tang, Eric ;

Dudley, Phillippa ;

James, Neil H. ;

Klinowska, Teresa ;

Davies, Barry R. .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (02) :446-454

[5] Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas [J].

Divakar, S. K. A. ;

Reddy, M. V. Ramana ;

Cosenza, S. C. ;

Baker, S. J. ;

Perumal, D. ;

Antonelli, A. C. ;

Brody, J. ;

Akula, B. ;

Parekh, S. ;

Reddy, E. Premkumar .

LEUKEMIA, 2016, 30 (01) :86-93

[6] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors [J].

Dobashi, Yoh ;

Suzuki, Shioto ;

Sato, Eiichi ;

Hamada, Yoshiki ;

Yanagawa, Takashi ;

Ooi, Akishi .

MODERN PATHOLOGY, 2009, 22 (10) :1328-1340

[7] Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts [J].

Ingels, Alexandre ;

Zhao, Hongjuan ;

Thong, Alan E. ;

Saar, Matthias ;

Valta, Maija P. ;

Nolley, Rosalie ;

Santos, Jennifer ;

Peehl, Donna M. .

INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (10) :2322-2329

[8] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention [J].

Jazirehi, AR ;

Bonavida, B .

ONCOGENE, 2005, 24 (13) :2121-2143

[9] Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E [J].

Julius, Annabelle ;

Desai, Anjali ;

Yung, Raymond L. .

ONCOTARGET, 2017, 8 (18) :30317-30327

[10] Long-range single domain array of a 5 nm pattern of supramolecules via solvent annealing in a double-sandwich cell [J].

Kwon, Kiok ;

Park, Kangho ;

Jung, Hee-Tae .

NANOSCALE, 2018, 10 (18) :8459-8470

← 1 2 3 4 →